Clinical Trials Browser

Recruiting × Erlotinib Hydrochloride × Clear all

NCT04981509 2026-04-07

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Phase 2 Recruiting

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT06997068 2026-04-03

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Phase 2 Recruiting

Mouth Neoplasms

NCT06483555 2026-04-01

PANGEA

Phase 1/2 Recruiting

DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT03297606 2026-03-27

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05442060 2025-08-03

EGFR

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

Neoplasms

NCT05525858 2025-04-27

KOSMOSII

Neoplasm Metastasis

NCT06071013 2025-01-23

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03192501 2024-06-25

iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray

Lung Neoplasms, Neoplasms

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms